

## April 2025 PDL/DUR Board Meeting Minutes

**Date:** April 16, 2025

**Members Present:** Barnhill, Caldwell, Jost, McGrane, Nauts, Oley

**Members Absent:** Anglim, Blake, Blank, Brown, Putsch

**Board Member Update:** The Board was notified that Jordan Stone has resigned from the DUR Board. Mountain Pacific will be vetting available retail pharmacists to fill this position.

**Others Present:** Shannon Sexauer, Dani Feist, Josh Surginer (DPHHS); Kathy Novak (Prime Therapeutics); Bahny, Miranda (Mountain Pacific); and representatives from the pharmaceutical industry.

**Public Comment:** Speaker information is as follows:

- Melinda Turkington, UCB – Bimzelx®
- Nirmal Ghuman, J&J – CAM & Cytokine Agents
- Erin Nowak, AbbVie – Rinvoq®
- Tyler Lincoln, Arcutis Biotherapeutics – Zoryve® 0.15% Cream
- Jen Leung, Incyte – Opzelura®
- Chris Dietrich, ARS Pharmaceuticals – Neffy®
- Natalie Rose, Gilead – Epclusa®
- Carla McSpadden, Galderma – Nemluvio®
- Cortney Patrick, Pfizer Medical Affairs – Paxlovid®

Written public comment was submitted to the Board prior to the meeting. It consisted of nine (9) manufacturer documents regarding Bimzelx®, Ebglyss®, Epclusa®, Fasenra®, Neffy®, Nemluvio®, Opzelura®, Tremfya®, and Zoryve®. The Board had no comments on these medications.

**Meeting Minute Review:** The meeting minutes from the March 19, 2025, PDL meeting were approved as written.

**Department Update:** No Department update.

### PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2025 RECOMMENDATIONS	GRANDFATHERED
ANTI-ALLERGENS, ORAL	NI - Palforzia®	Continue with PA criteria.	No
ANTIVIRALS, ORAL	ND - Paxlovid®  NI - oseltamivir	HSV Antivirals - Class effect. INFLUENZA Antivirals - Must have both oseltamivir and baloxavir marboxil. <i>Create new class for ANTIVIRALS, COVID - May add Paxlovid.</i>	No

BLADDER RELAXANTS	NI - Gemtesa®	Class effect. Must have one long-acting agent (either by half-life or dosage form), one anticholinergic, and one beta-3 receptor agonist.	No
COPD AGENTS	ND - Ohtuvayre®	Class effect. Must have a nebulizer product and a long-acting combination product.	No
CYTOKINES & CAM ANTAGONISTS	NI - Bimzelx®, Kevzara®, Omvoh®, Otezla®, Rinvoq®, Skyrizi®, Spevigo®, Tremfya®, biosimilars - adalimumab, ustekinumab, tocilizumab	Therapeutic alternatives. Do not add anakinra (Kineret®) due to inferior efficacy and increased toxicity. Grandfather.	Yes
EPINEPHRINE, SELF-ADMINISTERED <i>(class name changed from self-injected)</i>	ND - Neffy®	Class effect.	No
IMMUNOMODULATORS, ASTHMA	NI - Fasenra®, Xolair®	Therapeutic alternatives. Grandfathered class.	Yes
IMMUNOMODULATORS, ATOPIC DERMATITIS	ND - Ebglyss®, Nemluvio®  NI - Adbry®, Dupixent®, Zoryve®	Therapeutic alternatives. Continue PA criteria.	No
METHOTREXATE AGENTS	NI - Jylamvo®	Must have one oral and one injectable agent.	No

The Board reviewed the blue category in advance of the meeting. Kathy from Prime Therapeutics reported on new generics, updated indications, and drug availability changes in this category. This category of drugs has no new clinically significant information since the last review. Board recommendations for Group 2 (Blue category) from 2024 were retained with an adjustment to the BPH Agents class. The recommendations are as follows:

CLASS	2025 RECOMMENDATIONS	Grandfathered
ACNE AGENTS	BENZOYL PEROXIDE COMBOS - Class effect. BENZOYL PEROXIDE AGENTS - Class effect. CLINDAMYCIN AGENTS - Class effect.	No

	SODIUM SULFACETAMIDE AGENTS - Class effect. TOPICAL RETINOIDS & COMBOS - Class effect. ERYTHROMYCIN TOPICAL - Class effect.	
ANTIBIOTICS, GI	Must have metronidazole and vancomycin.	No
ANTIBIOTICS, INHALED	Therapeutic alternatives.	No
ANTIBIOTICS, TOPICAL	Must have a mupirocin product.	No
ANTIBIOTICS, VAGINAL	Therapeutic alternatives.	No

ANTIFUNGALS, ORAL	Must have terbinafine and fluconazole. Must have one of clotrimazole or nystatin. Continue PA criteria on ketoconazole.	No
ANTIFUNGALS, TOPICAL	Therapeutic alternatives for approved indications.	No
ANTIHISTAMINES, MINIMALLY SEDATING	Class effect. Must have one single ingredient agent.	No
ANTINEOPLASTIC AGENTS, TOPICAL	Therapeutic alternatives.	No
ANTIPARASITICS, TOPICAL	Therapeutic alternatives. Continue PA criteria.	No
ANTIPSORIATICS, TOPICAL	Class effect. Must have one topical formulation and a scalp formulation. Continue PA criteria.	No
ANTIVIRALS, TOPICAL	Class effect.	No
BPH AGENTS	ALPHA BLOCKERS - Class effect. ANDROGEN HORMONE INHIBITORS/COMBOS - Class effect. PDE-5 for BPH - <del>Tadalafil will be non-preferred.</del> Class effect. Continue with PA criteria. <i>(Removed "tadalafil will be non-preferred" statement, added "class effect", and kept continue with clinical criteria).</i>	No
BRONCHODILATORS, BETA AGONISTS	BETA AGONIST, LONG-ACTING - Class effect. BETA AGONIST, SHORT-ACTING - Class effect.	No
CEPHALOSPORINS & RELATED AGENTS	2 <sup>nd</sup> GENERATION - Class effect. 3 <sup>rd</sup> GENERATION - Class effect.	No
FLUOROQUINOLONES, ORAL	2 <sup>nd</sup> GENERATION - Class effect. Must have ciprofloxacin. 3 <sup>rd</sup> GENERATION - Class effect.	No
GLUCOCORTICOIDS, INHALED	Class effect. Must have one HFA option.	No
GLUCOCORTICOIDS, ORAL	SHORT ACTING - cortisone, hydrocortisone - Therapeutic alternatives. INTERMEDIATE ACTING - methylprednisolone, prednisone, and prednisolone - Therapeutic alternatives. Must include a dosepak.	No

	LONG ACTING - betamethasone, dexamethasone - Therapeutic alternatives. BUDESONIDE - Must have one budesonide.	
HEPATITIS C AGENTS	RIBAVIRINS - Class effect. PEGYLATED INTERFERONS - Do not add. ALL OTHERS - Therapeutic alternatives. Must have a pangenotypic agent. Continue with existing PA criteria. Grandfather.	Yes
IDIOPATHIC PULMONARY FIBROSIS	Therapeutic alternatives. Continue with existing PA criteria.	No
IMMUNOMODULATORS, TOPICAL	Therapeutic alternatives.	No
IMMUNOSUPPRESSANTS	Must have an entity of azathioprine, cyclosporine, mycophenolate, sirolimus, and tacrolimus. Grandfather.	Yes
INTRANASAL RHINITIS AGENTS	NASAL STEROIDS - Class effect. NASAL ANTIHISTAMINES & OTHERS - Class effect.	No
LEUKOTRIENE MODIFIERS	Must have montelukast.	No
MACROLIDES & KETOLIDES	Class effect. Must have azithromycin, clarithromycin, and erythromycin.	No
ROSACEA AGENTS, TOPICAL	Must have one metronidazole product.	No
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have varenicline.	No
STERIODS, TOPICAL	LOW, MEDIUM, HIGH, and VERY HIGH POTENCY CLASSES - Class effect for each class; must have one cream and one ointment from each category.	No
TETRACYCLINES	Must have doxycycline.	No

There were no Group 1 (green category) drugs to review.

The meeting was adjourned at 2:11 p.m.

The final PDL meeting for 2025 will be held on May 21, 2025, at 1:00 p.m., in this same format.